Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8551, Japan.
Cancer Treatment Center, Hiroshima University Hospital, Hiroshima, 734-8551, Japan.
J Gastroenterol. 2022 Sep;57(9):676-683. doi: 10.1007/s00535-022-01887-3. Epub 2022 Jul 18.
Intrahepatic cholangiocarcinoma is the second most common primary cancer of the liver. It is highly malignant and its prognosis is very poor. Although there have been various reports on the effects of calcium channel blockers on cancer, the effects of calcium channel blockers on intrahepatic cholangiocarcinoma have not been reported so far.
Seventy-nine patients diagnosed with intrahepatic cholangiocarcinoma by hepatectomy between January 2002 and May 2019 were retrospectively evaluated. We compared prognosis and time to recurrence between patients treated with calcium channel blockers (CCBs) (n = 29) and those not treated with CCBs (n = 50). Propensity score matching reduced confounding biases and yielded 25 matched patient pairs. Survival between groups was compared using Kaplan-Meier analyses, logrank tests, and Cox proportional hazard regression models.
Overall survival and recurrence-free survival of the CCBs group were significantly longer than those of the non-CCBs group OS in the original cohort and matched cohort (98 months vs 45 months, p = 0.010; 96 months vs 22 months, p = 0.020, respectively). Multivariate analyses showed that CCBs treatment was independently associated with overall survival (HR, 0.37; 95% CI 0.16-0.85; p = 0.019) and recurrence-free survival (HR, 0.39; 95% CI 0.17-0.90; p = 0.020) in the original cohort and matched cohort, respectively.
CCBs treatment might improve prognosis of patients with intrahepatic cholangiocarcinoma.
肝内胆管细胞癌是肝脏的第二大常见原发性癌症。它具有高度恶性，预后非常差。尽管有各种关于钙通道阻滞剂对癌症影响的报告，但迄今为止，尚未有关于钙通道阻滞剂对肝内胆管细胞癌影响的报道。
回顾性评估了 2002 年 1 月至 2019 年 5 月期间通过肝切除术诊断为肝内胆管细胞癌的 79 例患者。我们比较了接受钙通道阻滞剂（CCB）治疗（n=29）和未接受 CCB 治疗（n=50）的患者的预后和复发时间。倾向评分匹配降低了混杂偏差，并得出 25 对匹配的患者。使用 Kaplan-Meier 分析、对数秩检验和 Cox 比例风险回归模型比较组间生存情况。
CCB 组的总生存期和无复发生存期明显长于非 CCB 组（原始队列和匹配队列的 OS 分别为 98 个月 vs 45 个月，p=0.010；96 个月 vs 22 个月，p=0.020）。多变量分析显示，CCB 治疗与总生存期（HR，0.37；95%CI 0.16-0.85；p=0.019）和无复发生存期（HR，0.39；95%CI 0.17-0.90；p=0.020）独立相关，分别在原始队列和匹配队列中。
CCB 治疗可能改善肝内胆管细胞癌患者的预后。
